Scroll To Top

Gilead reduces price of Viread in developing countries

Gilead reduces price of Viread in developing countries

Pharmaceutical company Gilead Sciences announced it is cutting the price of its HIV nucleotide reverse transcriptase inhibitor Viread by 37% in 68 developing countries. The drug is already provided through the Gilead Access Program at a no-profit price to every country in Africa and 15 other nations categorized as "least developed" by the United Nations. The new price cut reflects improvements in the manufacturing process of Viread and increased economies of scale at Gilead. Viread will now be available in 68 poor nations for 82 cents per day. "We created the Gilead Access Program to make Viread available in resource-limited settings, and this price reduction will allow us to make it even more widely available," said company president and CEO John C. Martin. Gilead also announced Friday that it plans to make its fixed-dose combination pill containing Viread and its nucleoside reverse transcriptase inhibitor Emtriva available to poor nations through the program as soon as the combination pill receives Food and Drug Administration approval. An application for the pill was submitted to the FDA in March; a decision is expected by September.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff